About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maintenance Approaches
By
Nina Shah
9 Videos
August 29, 2017
0 Comments
Login to view comments.
Click here to Login
Featured Video
36:30
Bristol Myers Squibb Hematology
A Physician Perspective on Treating NSCT NDMM
Feat.
F. Davies
Featured Video
27:54
Bristol Myers Squibb Hematology
Importance of Maintenance Therapy in MM Patients Post Auto-HSCT
Feat.
B. Randolph
Related Content
AUTOPLAY
ON
23:18
Oncology Data Advisor
Can Diet and Nutrition Impact Multiple Myeloma Outcomes?
Feat.
U. Shah,
R. Banerjee
10:50
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …
Feat.
A. Jakubowiak
36:30
Bristol Myers Squibb Hematology
A Physician Perspective on Treating NSCT NDMM
Feat.
F. Davies
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
17:59
Parameswaran Hari
Delivering the Best Initial Treatment for Myeloma: Induction Therapy…
16:00
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…
Feat.
R. Baz
26:18
Morie Gertz
Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…
04:41
Joshua Richter
Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…
15:12
Yale Cancer Center
ASH 2021: Cellular Therapies in Myeloma
Feat.
N. Bar
27:54
Bristol Myers Squibb Hematology
Importance of Maintenance Therapy in MM Patients Post Auto-HSCT
Feat.
B. Randolph
22:41
Ehsan Malek
Importance and Prospect of Maintenance Treatment in Post-SCT MM Pati…
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Management of Multiple Myeloma: Smoldering Disease, Induction Therap…
Feat.
K. Shain
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…
Feat.
J. Brayer
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patient…
Feat.
T. Martin
05:09
Association of Community Cancer Centers (ACCC)
72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Di…
Feat.
K. Maples
13:27
Shaji Kumar
Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…
Feat.
A. Rosko
31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future P…
Feat.
M. Alsina
